A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors
Clinical trial NCT02799095 · COMPLETED
Trial details
- NCT number
- NCT02799095
- Sponsor
- Mural Oncology, Inc
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-09-14
- Primary completion
- 2023-03-27
- Enrollment
- 243
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.